CFTR Modulators for the Treatment of Cystic Fibrosis

Area of Science:

• Medical Genetics
• Pharmacology
• Pulmonology

Background:

• Cystic fibrosis (CF) is a monogenic disorder caused by mutations in the CFTR gene.
• Defective CFTR protein leads to impaired ion transport and mucus buildup.
• This genetic basis makes CF a prime target for precision medicine approaches.

Purpose of the Study:

• To highlight the potential of mutation-targeted therapies for cystic fibrosis.
• To review the current landscape of CFTR modulator drugs.

Main Methods:

• Literature review of existing CFTR modulators.
• Analysis of the genetic basis of cystic fibrosis.
• Examination of FDA-approved therapies and ongoing drug development.

Main Results:

• Single-gene defects in CFTR are responsible for cystic fibrosis.
• Ivacaftor is the only FDA-approved CFTR modulator currently available.
• Several other CFTR modulators are under active investigation and development.

Conclusions:

• Mutation-targeted therapy holds significant promise for treating cystic fibrosis.
• The development of novel CFTR modulators is crucial for expanding treatment options.